Journal Basic Info
- Impact Factor: 1.995**
- H-Index: 8
- ISSN: 2474-1647
- DOI: 10.25107/2474-1647
Major Scope
- Transplant Surgery
- Colon and Rectal Surgery
- Plastic Surgery
- Oral and Maxillofacial Surgery
- Breast Surgery
- Robotic Surgery
- Obstetrics Surgery
- Endocrine Surgery
Abstract
Citation: Clin Surg. 2022;7(1):3585.Case Report | Open Access
Combination of Amineptine and Gefitinib Overcome Acquired Resistance in T790M/trans-C797S-EGFRMutated Non-Small Cell Lung Cancer: A Case Report
Huibin Lv1, Shilei Zhao1, Jinguang Wang1 and Liu Yin2*
1Department of Thoracic Surgery, The First Affiliated Hospital of Dalian Medical University, China
2Department of Oncology, The First Affiliated Hospital of Dalian Medical University, China
PDF Full Text DOI: 10.25107/2474-1647.3585
Abstract
Osimertinib, a third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs), is the second-line treatment of choice for lung cancer patients who develop T790M mutation resistance after treatment with EGFR-TKIs, but resistance still inevitably occurs after use, and the mechanism of resistance and the choice of treatment regimen after resistance remain unclear. We report a case of right lung adenocarcinoma with intrapulmonary Metastasis (pT2N0M1b, stage IV) that developed T790M/trans-C797S-EGFR-mutate after and to provide clinical evidence of EGFR-TKIs in the treatment of lung cancer and to provide reference for future studies on the treatment of similar cases and the mechanism of resistance to Osimertinib.
Keywords
Cite the article
Lv H, Zhao S, Wang J, Yin L. Combination of Amineptine and Gefitinib Overcome Acquired Resistance in T790M/trans-C797SEGFR- Mutated Non-Small Cell Lung Cancer: A Case Report. Clin Surg. 2022; 7: 3585..
